Brind.

Analyst Comparison Highlights Valuation Differences Between Myriad Genetics and iBio

1 report, 1 independent Updated Oct 19
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A report compared Myriad Genetics and iBio, noting that 99.0% of Myriad Genetics shares are owned by institutional investors, compared to 7.9% for iBio. Analysts suggest iBio has a consensus target price of $5.83, implying a 661.23% upside, while Myriad Genetics has a consensus target price of $4.02, suggesting a 0.92% upside. Myriad Genetics has a beta of 1.64, meaning its stock price is 64% more volatile than the S&P 500, compared to iBio's beta of 1.26.

From themarketsdaily.com

Why it matters

Some supportBrind's analysis of the reports

The comparison highlights differing levels of institutional confidence and market expectations between the two companies. Strong institutional ownership and favorable analyst ratings can influence investor sentiment and future stock valuation.

From themarketsdaily.com

Who's involved

  • Myriad GeneticsAmerican biotechnology company whose stock is being analyzed
  • TD CowenAmerican investment bank that provides investment ratings and reports on Myriad Genetics stock

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped